I consent to Verdict Media Limited collecting my details provided via this form in accordance with Privacy Policy. Clinical Trial Agreements Software, Equipment & Diagnostic Agreements You either have scars from overpaying for services or not receiving expected payment for the services rendered. Clinical Trials (ISN-ACT) ISN-ACT Toolkit Study stage II: Ethics and regulatory requirements Contracts and Trial Agreements Contracts and trial agreements Trials conducted under regulatory agencies require contracts between the trial site and the clinical study sponsor or organization. Conducting Effective Negotiations Give your business an edge with our leading industry insights. Generally speaking, sites have to wait for the entire study results to be released before they can publish data on their subset of enrolled subjects. Overview of the Clinical Trial Agreement (CTA) Understanding the Terms of the Clinical Trial Agreement (CTA) Role of the Researcher and Site in Managing the Clinical Trial Agreement (CTA) Clinical Trial Agreement (CTA) Negotiation for Researchers and Sites Learn More The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. You can find the document on our dedicatedHRA Approval page. A confidential disclosure agreement (CDA) details obligations surrounding the disclosure of confidential information and how this type of data will be safeguarded. PDF Clinical Trial Agreements - American Health Lawyers Association www.umc.edu, General Information: 601-984-1000 The bullet points below illustrate the CTA/CSA process for industry-sponsored clinical research studies: OCT negotatiator reviews and revises the agreement, which is uploaded to an electronic contract routing system (3 business days), Office of Intellectual Property and Commercialization, Office of General Counsel, Office of Integrity and Compliance, Division of Information Systems, and Office of Information Security review and revise the agreement (15 business days), OCT negotiator compiles changes and sends CTA/CSA response to sponsor or CRO (3 business days), OCT negotiates the CTA/CSA with the sponsor or CRO until finalization (2 business days per party, not to exceed 30 calendar days). For example, once the site is activated for enrollment, a site start-up payment is triggered. You want to document the overarching purpose of the agreement in this section. PDF Contract Negotiations for Clinical Trials - a G This cookie is set by GDPR Cookie Consent plugin. Clinical Trial Agreement | CCTS - Ohio State University If you are part of one of these groups, please reach out to your study implementation or finance team for assistance with the CTA. The Period of Performance under this Agreement shall be Which of these nine CTA components did you find most useful? Sites want to get paid for their research services. The model Industry Collaborative Research Agreement (mICRA) launched in February 2011 aims to support clinical research collaborations involving the pharmaceutical and biotechnology industries, academia and NHS organisations across the UK. This cookie is set by Polylang plugin for WordPress powered websites. Necessary cookies are absolutely essential for the website to function properly. If you will be seeking HRA Approval for your study, you may also find it useful to refer to the HRA assessment criteria and standards document as this includes considerations around the use of model agreements. Model site agreements (model contracts, standard research agreements), Participant in research experience survey, National Directive on Commercial Contract Research Studies. PDF Clinical Trials Site Agreement - University College London With the use of the Accelerated Confidential Disclosure Agreement template, protocols can be obtained by participating sites without confidentiality agreement negotiation delays, placing those sites at an advantage to initiating trials earlier than current processes permit. This is where the payment schedule comes handy. Site may realize there is more work involved on a trial than they had anticipated. These cookies are set via embedded youtube-videos. In the event of any inconsistency between this Agreement and the Protocol, the terms of this Agreement shall govern. This cookie is set by Adobe ColdFusion applications. Types of Clinical Trial Agreements Clinical Trial Agreement Ensuring subject injury language is drafted in accordance with national laws and regulations, such as Medicare. But opting out of some of these cookies may affect your browsing experience. details around the PI (and possibly sub-investigators); including detail about what happens if the PI is no longer involved in the study for some reason. A vaccine takes between 5 and 10 years to develop. Payment and reimbursement procedures and requirements. Contracts and Trial Agreements - International Society of Nephrology General purpose platform session cookies that are used to maintain users' state across page requests. Sponsors are committed to reporting trial results on ethical grounds. administrative arrangements of Scotland, Wales and Northern Ireland. It's important to consider the rules of your institution, as public and non-profit educational and research institutions are bound by specific policies and regulations to protect the welfare of human subjects and minimize liability. Additionally, this section includes other agreements, such as the sponsor's right to audit the site or verify data on a regular basis, and the sites responsibility to cooperate with the sponsor or a regulatory agency, such as the FDA. Suggested Audiences: Individuals involved in CTA development as well as CTA negotiation and execution, Principal Investigators (PIs), Research Staff and Administrators, Organizational Subscription Price: Included with Human Subjects Research series, available as part of an organizational subscription package or for $1,000 as an add-on to current subscriptions.Independent Learner Price: $29 per person. Clinical Trials Negotiation Basics | Offices of Sponsored Programs and This cookie is set by linkedIn. It also outlines what should be addressed in the key sections of the CTA and the aim for each section. Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. This article takes a short look at the basic sections in most Clinical Trial Agreements (CTAs) between clinical trial sponsors (Sponsors) and clinical trial sites (Sites) in the United States. As an example, consider vaccines. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites. Whether you are new to clinical research agreements or a contracts ninja, at any given moment there is at least one agreement you can think of that could have been worded differently. By dismissing this banner, you are rejecting all cookies and therefore we will not store any cookies on this device. For more information and to access the latest versions of model agreement templates, visit the IRAS website. Pharmaceutical industry stakeholders are you ready for the future? If you are part of one of these groups, please reach out to your study implementation or finance team for assistance with the CTA. details around adverse events and safety reporting, a statement around acceptable protocol deviations, if any, and. Additionally, in some cases, payments are triggered when certain milestones are met. modified model agreement, or an agreement not based on a model template is There is serious responsibility on the part of sponsors, CROs and sites to comply with the study protocol, government laws and regulations. He enjoys connecting like-minded people, introducing new ideas, and immersing himself in an environment of continuous learning. PDF SOP-08: Site Initiation Visits - Ohio State University Just like your auto or health insurance policy, sites, CROs and sponsors generally carry clinical trial insurance to protect themselves or the parties involved in a clinical trial. If you have a disability and experience difficulty accessing this content, contact our webmaster at ccts-info@osumc.edu.Notice of Non-Discrimination, Each CTA is signed byan authorized signatory within the Office of Sponsored Programs on behalf of the University. 1. The cookie is used to store the user consent for the cookies in the category "Performance". A Clinical Trial Agreement (CTA) or Clinical Study Agreement (CSA) is a direct agreement between the sponsor or the CRO and it establishes the terms and conditions of the clinical trial. Was this document helpful? Research Study Budget Design and Analysis, The Ohio State University Wexner Medical Center. As sponsor and site, you want to prepare yourself for contract termination. For studies under HRA Approval, the HRA Initial Assessment This cookie is native to PHP applications. Please note that this page has been updated for 2015 following a quality check and review of the templates, and many new ones have been added. A Clinical Trials Agreement is a (non-FDA) phrase referring to the financial arrangements between an investigative site and a sponsor. In the event there is a compliance audit questioning financial payments to the research site, the project description can provide clarity. Hiring activity related to social responsibility increased by 10% in the pharmaceutical industry in Q3 2022, Hiring activity related to artificial intelligence increased by 7% in the pharmaceutical industry in Q3 2022, Quarterly Hiring Update: Hiring activity related to cloud decreased by 8% in the pharmaceutical industry in Q3 2022, How to ensure transparency in your clinical trial, Three ways to improve participant engagement in your digital clinical trials, How Israel and Turkey are growing markets for clinical trials. Access the suite of model agreements Interactive Campus Map Clinical Trial Agreements in the US: The Basics - LinskLaw Also sites would be required to submit the manuscript to the sponsor review prior to making a journal submission. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. a discussion around use of study supplies, materials and equipment and possibly a reference to an additional Appendix that will list all the equipment and set out any additional equipment-specific contractual requirements. There are several different model agreements, and you should use the one that is most appropriate for your study type and sponsorship arrangements. The FUA is technically a "clinical trial agreement" as it is an agreement directly relating to the operations of a clinical trial, but it is not a . If agreed on a signed CTA, sponsors will have the right to data collected prior to contract termination and sites will receive compensation for trial activities performed by the research staff. It's important to ensure that acceptable contract clauses are developed for important issues that include indemnification, data and intellectual property ownership, patent and publication rights, confidentiality, and subject injury. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. Let me know by leaving a comment below. Investigator-Initiated Multi-Site Clinical Trials - NHLBI, NIH Kunal is the founder of the Clinical Trial Podcast, a podcast and blog platform for clinical research professionals. Contracts and Agreements - ScienceDirect Clinical Trial Agreement Definition: What You Need to Know - UpCounsel CTA with an academic institution, typically used for a subcontract or subaward when another site is brought in to assist with a clinical trial. Internet Explorer is no longer supported by Microsoft. Learn More; Model agreements - Health Research Authority A clinical trial agreement definition outlines the governing terms and obligations that apply to all parties when a clinical trial is conducted. ), it is expected that a signed agreement between the sponsor and the host organisation will be in place before the research commences at the site. Types of Agreements 3. Please click on the orange text to download each template. Indemnification may be a fancy word youve never heard before, but the concept behind this term is fairly straightforward. It is a consistent evaluation aimed at discovering a more effective strategy to prevent, diagnose, or treat a condition. Clinical Trial Agreements - CDG Whitepapers You also have the option to opt-out of these cookies. Unmodified use is a general expectation and, in some cases, an obligation for the NHS - as set out in the National Directive on Commercial Contract Research Studies. The purpose of this section is to explicitly state the research project description. The .gov means its official.Federal government websites often end in .gov or .mil. 1. The cookie is set by Wix website building platform on Wix website. PDF CLINICAL TRIAL AGREEMENT - University of Rochester Clinical research studies are essential to translate knowledge gained in the laboratory into interventions that improve human health. If you would like to learn more about how I can help you with the legal review of CTAs for your next clinical trial, please contact me here. This site uses session cookies and persistent cookies to improve the content and structure of the site. CTA with an industry sponsor, which can be either investigator- or sponsor-initiated. Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. This is used to present users with ads that are relevant to them according to the user profile. Search for FDA Guidance Documents, Recalls, Market Withdrawals and Safety Alerts, Search General and Cross-Cutting Topics Guidance Documents, Decentralized Clinical Trials for Drugs, Biological Products, and Devices, Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers, Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products, Clinical Investigator Administrative Actions Disqualification, Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment, Tissue Agnostic Drug Development in Oncology, Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials, Ethical Considerations for Clinical Investigations of Medical Products Involving Children, Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations, Investigator Responsibilities Safety Reporting for Investigational Drugs and Devices, Sponsor ResponsibilitiesSafety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies Guidance for Industry, Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1), Enhancing the Diversity of Clinical Trial Populations Eligibility Criteria, Enrollment Practices, and Trial Designs, Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank, Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological ProductsContent and Format, Conduct of Clinical Trials of Medical Products during COVID19 Public Health Emergency, Providing Regulatory Submissions in Electronic Format Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, Adaptive Design Clinical Trials for Drugs and Biologics, Postmarketing Studies and Clinical Trials - Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act, Humanitarian Device Exemption (HDE) Program, Humanitarian Use Device (HUD) Designations, ICH E8(R1): General Considerations for Clinical Studies, Clinical Lactation Studies: Considerations for Study Design, Risk-Based Approach to Monitoring of Clinical Investigations: Questions and Answers, Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials, Impact of Certain Provisions of the Revised Common Rule on FDARegulated Clinical Investigations, ICH E17: General Principles for Planning and Design of MultiRegional Clinical Trials, Institutional Review Board (IRB) Written Procedures, ICH E11(R1): Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population, Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials, ICH E6(R2): Good Clinical Practice: Integrated Addendum to ICH E6(R1), Acceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions, Payment and Reimbursement to Research Subjects, Investigational IVDs Used in Clinical Investigations of Therapeutic Products, Waiver of IRB Requirements for Drug and Biological Product Studies, Individual Patient Expanded Access Applications: Form FDA 3926, Minutes of Institutional Review Board (IRB) Meetings, Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies, IRB Waiver or Alteration of Informed Consent for Clinical Investigations Involving No More Than Minimal Risk to Human Subjects, Use of Electronic Records and Electronic Signatures in Clinical Investigations Under 21 CFR Part 11 Questions and Answers, Form FDA 3674 Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions, Emergency Use Authorization of Medical Products and Related Authorities, Use of Electronic Informed Consent in Clinical Investigations Questions and Answers, Clinical Considerations for Investigational Device Exemptions (IDEs) for Neurological Devices Targeting Disease Progression and Clinical Outcomes, Collection of Race and Ethnicity Data in Clinical Trials, Adaptive Designs for Medical Device Clinical Studies, Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information, Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices, Charging for Investigational Drugs Under an IND Questions and Answers, Expanded Access to Investigational Drugs for Treatment Use Questions and Answers, Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails, Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products Content and Format Guidance for Industry (Small Entity Compliance Guide), Evaluation of Sex-Specific Data in Medical Device Clinical Studies, Considerations When Transferring Clinical Investigation Oversight to Another IRB, Meaning of "Spouse" and "Family" in FDA's Regulations after the Supreme Court's Ruling in United States v. Windsor: Questions and Answers, Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only, Design Considerations for Pivotal Clinical Investigations for Medical Devices, Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies, Electronic Source Data in Clinical Investigations, Investigational New Drug Applications (INDs) Determining Whether Human Research Studies Can Be Conducted Without an IND, IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed, Oversight of Clinical Investigations A Risk-Based Approach to Monitoring, Exception from Informed Consent Requirements for Emergency Research, Financial Disclosure by Clinical Investigators, ICH E3: Structure and Content of Clinical Study Reports, Questions and Answers, Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies, Safety Reporting Requirements for INDs and Bioavalability/Bioequivalence (BA/BE) Studies Small Entity Compliance Guide, FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions, ICH E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers, IRB Continuing Review After Clinical Investigation Approval, Informed Consent Elements, 21 CFR 50.25(c), Questions and Answers, Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application, In Vitro Diagnostic (IVD) Device Studies Frequently Asked Questions, Statement of Investigator (Form FDA 1572) Frequently Asked Questions, FDA Inspections of Clinical Investigators, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects, IRB Registration Frequently Asked Questions, Adverse Event Reporting to IRBs Improving Human Subject Protection, Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices, Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials, Current Good Manufacturing Practice for Phase 1 Investigational Drugs, Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions, Computerized Systems Used in Clinical Investigations, Process for Handling Referrals to FDA Under 21 CFR 50.54 Additional Safeguards for Children in Clinical Investigations, ICH E5 Ethnic Factors in the Acceptability of Foreign Clinical Data, Questions and Answers, Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable, Establishment and Operation of Clinical Trial Data Monitoring Committees, Using a Centralized IRB Review Process in Multicenter Clinical Trials, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products Content and Format, Medical Devices Frequently Asked Questions, Significant Risk and Nonsignificant Risk Medical Device Studies, FDA Institutional Review Board Inspections, Development and Use of Risk Minimization Action Plans, Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, Use of Clinical Holds Following Clinical Investigator Misconduct, Independent Consultants for Biotechnology Clinical Trial Protocols, Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples, Financial Conflict of Interest: HHS Guidance (2004), IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer, Part 11, Electronic Records; Electronic Signatures Scope and Application, IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations, INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information, Food-Effect Bioavailability and Fed Bioequivalence Studies, General Principles of Software Validation, ICH E10: Choice of Control Group and Related Issues in Clinical Trials, ICH E11: Clinical Investigation of Medicinal Products in the Pediatric Population, Clinical Holds Submitting and Reviewing Complete Responses, Categories of Research That May Be Reviewed Through an Expedited Review Process, ICH E5: Ethnic Factors in the Acceptability of Foreign Clinical Data, Evaluation of Gender Differences in Clinical Investigations, Institutional Review Boards Frequently Asked Questions, Sponsor-Investigator-IRB Interrelationship, Screening Tests Prior to Study Enrollment, Use of Investigational Products When Subjects Enter a Second Institution, Off-Label and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices, Emergency Use of an Investigational Drug or Biologic, Clinical Investigator Regulatory Sanctions Information Sheet, ICH E8: General Considerations for Clinical Trials, Design Control Guidance For Medical Device Manufacturers, ICH E3: Structure and Content of Clinical Study Reports, ICH E7: Studies in Support of Special Populations: Geriatrics, Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs, Clinical Trials and Human Subject Protection, Electronic Code of Federal Regulations (eCFR), Websites with Information about Clinical Trials, Real World Data/Real World Evidence (RWD/RWE), Disqualification, Good Clinical Practice (GCP), Human Subject Protection (HSP), Investigator, Inspection, Good Clinical Practice (GCP), Human Subject Protection (HSP), Investigator, 1572, HIPAA, Human Subject Protection (HSP), Investigation, Design, Diversity, Ethics Committee (EC), Ethnicity, Gender, Good Clinical Practice (GCP), Human Subject Protection (HSP), Civil Money Penalties, clinicaltrials.gov, Design, Investigation, Labeling, Lactation, Pregnancy, Sponsor, Coronavirus, COVID, Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Investigation, Electronic, Investigational New Drug (IND), Part 11, Records, Design, Good Clinical Practice (GCP), Investigation, Sponsor, Clinical Medical, Design, Good Clinical Practice (GCP), Investigation, Sponsor, Bioavailability, design, drug safety, good clinical practice, investigation, postmarketing, Exemption, Humanitarian Device Exemption (HDE), Humanitarian Use Device (HUD), Medical Device, Ethics Committee (EC), Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), International Conference on Harmonization (ICH), Records, Sponsor, Design, Investigation, Lactation, Sponsor, Clinical, Design, Efficacy, Variability, Protocol, Exclusion, Inclusion, Genomic, Children, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Pediatric, Common Rule, Human Subject Protection (HSP), Institutional Review Board (IRB), Design, Ethics Committee (EC), Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), International Conference on Harmonization (ICH), Records, Sponsor, Institutional Review Board (IRB), Records, Children, Ethics Committee (EC), Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), International Conference on Harmonization (ICH), Records, Sponsor, Gender, Human Subject Protection (HSP), Institutional Review Board (IRB), Investigation, Pregnancy, Ethics Committee (EC), Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Sponsor, Good Clinical Practice (GCP), Investigation, Investigational Device Exemption (IDE), Medical Device, Human Subject Protection (HSP), Informed Consent, Good Clinical Practice (GCP), In Vitro Diagnostic (IVD), Investigation, Investigational Device Exemption (IDE), Investigational New Drug (IND), Labeling, Medical Device, Sponsor, Human Subject Protection (HSP), Institutional Review Board (IRB), Waiver, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Investigation, Investigational New Drug (IND), Demographic, Diversity, Ethnicity, Gender, Investigation, Medical Device, Pediatric, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Waiver, Good Clinical Practice (GCP), Human Subject Protection (HSP), Electronic, Investigation, Part 11, Records, Certify, Certification, clinicaltrials.gov, Medical Device, Emergency, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Investigation, Investigational New Drug (IND), Electronic, Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Part 11, Records, Advisory Committees, Clinical Medical, Good Clinical Practice (GCP), Humanitarian Device Exemption (HDE), Humanitarian Use Device (HUD), Labeling, Laser Notice, Medical Device, Neurological, Premarket, Premarket Approval (PMA), Safety, Sponsor, Good Clinical Practice (GCP), Humanitarian Device Exemption (HDE), Humanitarian Use Device (HUD), Investigational Device Exemption (IDE), Medical Device, Premarket, Premarket Approval (PMA), Sponsor, 510k, Chemistry Manufacturing Controls (CMC), Good Clinical Practice (GCP), Investigation, Sponsor, Children, Human Subject Protection (HSP), Medical Device, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Demographic, Design, Gender, Good Clinical Practice (GCP), Medical Device, Premarket, Sponsor, Informed Consent, Institutional Review Board (IRB), In Vitro, Investigation, Medical Device, Specimen, Design, Good Clinical Practice (GCP), Investigation, Medical Device, Premarket, Sponsor, Institutional Review Board (IRB), Investigation, Medical Device, Safety, Good Clinical Practice (GCP), Electronic, Part 11, Records, Institutional Review Board (IRB), Investigation, Investigational New Drug (IND), Institutional Review Board (IRB), Investigational Device Exemption (IDE), Investigational New Drug (IND), Investigator, Medical Device, Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Financial Disclosure, Good Clinical Practice (GCP), Good Clinical Practice (GCP), International Conference on Harmonization (ICH), Sponsor, Bioavailability, Bioequivalence, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Safety, Design, Diversity, Ethnicity, Gender, International Conference on Harmonization (ICH), Sponsor, Continuing Review, Institutional Review Board (IRB), Good Clinical Practice (GCP), Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Investigational New Drug (IND), Human Subject Protection (HSP), In Vitro, Informed Consent, Medical Device, Specimen, Good Clinical Practice (GCP), Human Subject Protection (HSP), Inspection, Investigator, Investigation, Investigational New Drug (IND), Product Development, Clinical Investigator, Institutional Review Board (IRB), Institutional Review Board (IRB), Registration, Institutional Review Board (IRB), Report, Safety, Drug, Labeling, Practice, Medical Device, Medicine, Sponsor, Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Investigation, In Vitro Diagnostic (IVD), Laboratory Developed Test (LDT), Medical Device, Reagent, Children, Human Subject Protection (HSP), Informed Consent, Institutional Review BA/BEoard (IRB), Pediatric, Design, Diversity, Ethics Committee (EC), Ethnicity, Gender, Human Subject Protection (HSP), Institutional Review Board (IRB), International Conference on Harmonization (ICH), Sponsor, Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), Institutional Review Board (IRB), Multicenter, Single, Institutional Review Board (IRB), Medical Device, Risk, Safety, Human Subject Protection (HSP), Institutional Review Board (IRB), Inspection, Good Clinical Practice (GCP), Investigational New Drug (IND), Risk, Safety, Clinical Medical, Good Clinical Practice (GCP), Good Clinical Practice (GCP), Hold, Investigation, Investigational New Drug (IND), Investigator, Misconduct, Financial Disclosure, Good Clinical Practice (GCP), Institutional Review Board (IRB), Exemption, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Electronic, Good Clinical Practice (GCP), Part 11, Records, Chemistry Manufacturing Controls (CMC), Investigation, Investigational New Drug (IND), Sponsor, Bioavailability, Bioequivalence, Drug, Food, Investigational New Drug (IND), Electronic, Investigation, Medical Device, Part 11, Quality, Risk, Software, Validation, Good Clinical Practice (GCP), Hold, Investigation, Investigational New Drug (IND), Investigator, Expedited Review, Good Clinical Practice (GCP), Human Subject Protection (HSP), Institutional Review Board (IRB), Design, Diversity, Ethics Committee (EC), Ethnicity, Gender, International Conference on Harmonization (ICH), Sponsor, Demographic, Gender, Good Clinical Practice (GCP), Human Subject Protection (HSP), Investigation, Investigational New Drug (IND), Human Subject Protection (HSP), Institutional Review Board (IRB), Good Clinical Practice (GCP), Institutional Review Board (IRB), Investigator, Sponsor, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Medical Device, Human Subject Protection (HSP), Informed Consent, Institutional Review Board (IRB), Recruit, Recruitment, Human Subject Protection (HSP), Informed Consent, Recruit, Recruitment, Human Subject Protection (HSP), Informed Consent, Investigation, Investigational Device Exemption (IDE), Investigational New Drug (IND), Institutional Review Board (IRB), Medical Device, Investigation, Investigational New Drug (IND), Medical Device, Practice of Medicine, Emergency, Human Subject Protection (HSP), Informed Consent, Investigational New Drug (IND), Institutional Review Board (IRB), Human Subject Protection (HSP), Investigation, Investigational New Drug (IND), Institutional Review Board (IRB), Design, Good Clinical Practice (GCP), Investigation, Investigational New Drug (IND), Sponsor, Good Clinical Practice (GCP), Investigator, Sanction, Design, Good Manufacturing Practice (GMP), Medical Device, Sponsor, Ethics Committee (EC), Design, Diversity, Ethnicity, Gender, Human Subject Protection (HSP), International Conference on Harmonization (ICH), Sponsor.